These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10159282)

  • 1. A pharmacoeconomic study of the management of major depression: patients in a TennCare HMO.
    Smith W; Sherrill A
    Med Interface; 1996 Jul; 9(7):88-92. PubMed ID: 10159282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in the cost of antidepressants across state Medicaid programs.
    Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
    J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population.
    McCombs JS; Nichol MB; Stimmel GL; Sclar DA; Beasley CM; Gross LS
    J Clin Psychiatry; 1990 Jun; 51 Suppl():60-9; discussion 70-1. PubMed ID: 2189876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilization, price, and spending trends for antidepressants in the US Medicaid Program.
    Chen Y; Kelton CM; Jing Y; Guo JJ; Li X; Patel NC
    Res Social Adm Pharm; 2008 Sep; 4(3):244-57. PubMed ID: 18794035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antidepressants consumption in the global population in France].
    Olié JP; Elomari F; Spadone C; Lépine JP
    Encephale; 2002; 28(5 Pt 1):411-7. PubMed ID: 12386542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic impact of non-persistence to antidepressant therapy in the Quebec community-dwelling elderly population.
    Tournier M; Moride Y; Crott R; du Fort GG; Ducruet T
    J Affect Disord; 2009 May; 115(1-2):160-6. PubMed ID: 18694602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depression diagnoses and antidepressant use in primary care practices: a study from the Practice Partner Research Network (PPRNet).
    Ornstein S; Stuart G; Jenkins R
    J Fam Pract; 2000 Jan; 49(1):68-72. PubMed ID: 10678342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization.
    Sclar DA; Robison LM; Skaer TL; Galin RS; Legg RF; Nemec NL; Hughes TE; Buesching DP; Morgan M
    J Int Med Res; 1995; 23(6):395-412. PubMed ID: 8746607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of usual general practitioner care with or without antidepressant medication for patients with minor or mild-major depression.
    Bosmans JE; Hermens ML; de Bruijne MC; van Hout HP; Terluin B; Bouter LM; Stalman WA; van Tulder MW
    J Affect Disord; 2008 Nov; 111(1):106-12. PubMed ID: 18342952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and economic impact of antidepressant medications: a review.
    Mitchell J; Greenberg J; Finch K; Kovach J; Kipp L; Shainline M; Jordan N; Anderson C
    Am J Manag Care; 1997 Feb; 3(2):323-30; quiz 331. PubMed ID: 10169266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Service utilization and associated direct costs for bipolar disorder in 2004: an analysis in managed care.
    Stensland MD; Jacobson JG; Nyhuis A
    J Affect Disord; 2007 Aug; 101(1-3):187-93. PubMed ID: 17254637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A critical review of selected pharmacoeconomic analyses of antidepressant therapy.
    Conner TM; Crismon ML; Still DJ
    Ann Pharmacother; 1999 Mar; 33(3):364-72. PubMed ID: 10200863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic impact of nonpersistence with antidepressant treatment in the adult population of Quebec: a comparative cost-effectiveness approach.
    Béland SG; Tournier M; Galbaud du Fort G; Crott R; Ducruet T; Pariente A; Moride Y
    Value Health; 2011 Jun; 14(4):492-8. PubMed ID: 21669374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effective treatment of depression with selective serotonin reuptake inhibitors.
    Panzarino PJ; Nash DB
    Am J Manag Care; 2001 Feb; 7(2):173-84. PubMed ID: 11216334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term costs of treatment for depression: impact of drug selection and guideline adherence.
    Crown WH; Treglia M; Meneades L; White A
    Value Health; 2001; 4(4):295-307. PubMed ID: 11705297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost burden of treatment resistance in patients with depression.
    Gibson TB; Jing Y; Smith Carls G; Kim E; Bagalman JE; Burton WN; Tran QV; Pikalov A; Goetzel RZ
    Am J Manag Care; 2010 May; 16(5):370-7. PubMed ID: 20469957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of medication in managed care for depression.
    Glazer WM; Rosenbaum JF
    J Clin Psychiatry; 1998; 59 Suppl 2():67. PubMed ID: 9559762
    [No Abstract]   [Full Text] [Related]  

  • 18. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline.
    Russell JM; Berndt ER; Miceli R; Colucci S; Grudzinski AN
    Am J Manag Care; 1999 May; 5(5):597-606. PubMed ID: 10537866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective analysis of the health-care costs of bupropion sustained release in comparison with other antidepressants.
    Poret AW; Neslusan C; Ricci JF; Wang S; Khan ZM; Kwong JW
    Value Health; 2001; 4(5):362-9. PubMed ID: 11705126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year costs of second-line therapies for depression.
    Sullivan EM; Griffiths RI; Frank RG; Strauss MJ; Herbert RJ; Clouse J; Goldman HH
    J Clin Psychiatry; 2000 Apr; 61(4):290-8. PubMed ID: 10830151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.